Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Aug 5, 2010


Title: Compositions and Methods for Inhibiting Expression of Anti-Apoptotic Genes

Patent Number: 7,767,802

Filed: Sept. 15, 2004

Inventor: Hans-Peter Vornlocher, Alnylam Pharmaceuticals

The invention relates to a "double-stranded ribonucleic acid for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as a Bcl gene," the patent's abstract states. "The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell."

Title: E. coli-Mediated Gene Silencing of Beta-Catenin

Application Number: 20100189691

Filed: Nov. 13, 2009

Lead Inventor: Johannes Fruehauf, Cequent Pharmaceuticals (Marina Biotech)

The invention, the patent application's abstract states, comprises "methods … for the delivery of one or more small interfering RNAs to a eukaryotic cell using a bacterium or [bacterial therapeutic particle, as well as] … methods for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference and methods for treating viral diseases and disorders. The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells."

Title: Pharmaceutical Composition and Pharmaceutical Kit for the Treatment of Hepatocellular Carcinoma

Application Number: 20100189775

Filed: July 25, 2007 PCT Filed: July 25, 2007

Lead Inventor: Luigi Bolondi, Center for Applied Biomedical Research

The invention "provides pharmaceutical compositions for the treatment of hepatocellular carcinoma comprising Notch3 inhibitors and a chemotherapeutic agent, methods for the preparation of said compositions, and a medical treatment comprising the administration of said pharmaceutical compositions in patients in need thereof," the patent application's abstract states.

The application specifically claims an siRNA or shRNA inhibitor of Notch3.

Title: siRNA-Mediated Gene Silencing with Viral Vectors

Application Number: 20100190243

Filed: Aug. 24, 2009

Lead Inventor: Beverly Davidson, University of Iowa

The invention "is directed to viral vectors encoding small interfering RNA molecules targeted against a gene of interest, and methods of using these viral vectors," the patent application's abstract states.

Title: Delivery of Nucleic Acids Using Cell-Penetrating Peptides

Application Number: 20100190691

Filed: Jan. 26, 2010

Lead Inventor: Agamemnon Epenetos, Trojan Technologies

The invention, the patent application's abstract states, "is based on the … concept of conjugating a cell-penetrating peptide, including a protein transduction domain, to a nucleic acid molecule to provide a nucleic acid-protein conjugate exhibiting enhanced cellular uptake. Accordingly, the invention provides a method of producing a cell-permeable nucleic acid molecule conjugate nucleic acid including a nucleic acid conjugated with a homeodomain of an antennapedia homeotic transcription factor protein, or functional fragment thereof. The invention further provides compositions and methods treating a subject using the conjugates produced by the method described herein."

Title: RNAi Inhibition of Alpha-ENaC Expression

Application Number: 20100190714

Filed: Jan. 6, 2010

Lead Inventor:
Gino Van Heeke, Novartis

"The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression, by chemically modified oligonucleotides," according to the patent application's abstract.

Title: Influenza Polynucleotides, Expression Constructs, Compositions, and Methods of Use

Application Number: 20100190842

Filed: April 14, 2008 PCT Filed: April 14, 2008

Lead Inventor: Catherine Pachuk, Alnylam Pharmaceuticals

"The invention provides isolated RNA molecules containing a stretch of nucleotides from a conserved influenza sequence, [as well as] complementary RNA molecules thereto," the patent application's abstract states. "The RNA molecules of the invention are also substantially non-homologous to human sequences. The RNA molecules of the invention include double-stranded RNAs comprising a first region that is a conserved influenza sequence, and a second region that is at least substantially complementary to the first region. Such double-stranded RNAs include single short hairpin RNAs, as well as multi-target hairpin RNAs containing a plurality, or several, stem-loop structures."

The invention further provides "expression constructs that provide for expression of one, or a plurality, of RNA molecules of the invention," the abstract adds. "The RNA molecules, expression constructs, and compositions of the … invention find use in reducing levels of influenza A RNA, in reducing influenza A virus titer, and in treating or preventing influenza virus infection. The invention is effective against at least human, swine, and avian originating strains of influenza A, and makes gene-silencing therapeutic strategies for combating influenza A infection feasible."

Title: siRNA Targeting Diacylglycerol O-Acyltransferase Homolog 2

Application Number: 20100190971

Filed: March 1, 2010

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for DGAT2."

Title: Methods for Controlling Gene Expression Using Ta-siRA

Application Number: 20100192237

Filed: Sept. 20, 2006 PCT Filed: Sept. 20, 2006

Lead Inventor: Peifeng Ren, BASF Plant Science

The invention comprises "agents capable of controlling gene expression," according to the patent application's abstract. "More specifically the inventions relates to methods for engineering [trans-acting siRNA] primary transcripts in order to target [genes of interest] and control their expression. The invention further provides for a method for modulating transgenic expression by said engineered ta-siRNAs."

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.